<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885156</url>
  </required_header>
  <id_info>
    <org_study_id>MUS 90200_3028_1</org_study_id>
    <nct_id>NCT01885156</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris</brief_title>
  <official_title>A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see how well Naftin 1% cream works when applied once daily to the affected area. The&#xD;
      results will be compared to those using a placebo cream, which is a cream with no active&#xD;
      ingredient. Safety will also be measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).</measure>
    <time_frame>Week 6</time_frame>
    <description>- Summarization of AEs (local and systemic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).</measure>
    <time_frame>Week 6</time_frame>
    <description>Complete Cure based on:&#xD;
-Negative mycology results; absence (Grade 0) of erythema, scaling, and pruritis&#xD;
Other efficacy variables assessed at Week 2, Week 4, and Week 6:&#xD;
Effective treatment&#xD;
Mycological cure&#xD;
Clinical Success&#xD;
Clinical Cure&#xD;
Investigator Global Assessment&#xD;
Subject Satisfaction Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Tinea Cruris</condition>
  <condition>Jock Itch</condition>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topically applied once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin 1% Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topically applied once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin 1% Cream</intervention_name>
    <description>Topically applied once a day</description>
    <arm_group_label>Naftin 1% Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Topically applied once a day</description>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Review and sign statement of Informed Consent and HIPAA authorization.&#xD;
&#xD;
          -  Males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or&#xD;
             sex. Females of child-bearing potential must have a negative urine pregnancy test.&#xD;
&#xD;
          -  The parent/legal guardian must complete the informed consent process AND the subject&#xD;
             must complete the assent process and sign the appropriate form (if age appropriate).&#xD;
&#xD;
          -  Presence of tinea cruris characterized by clinical evidence of a tinea infection (at&#xD;
             least moderate erythema, moderate scaling, and mild pruritus) based on signs and&#xD;
             symptoms.&#xD;
&#xD;
          -  KOH positive baseline skin scrapings obtained from the site most severely affected or&#xD;
             a representative site of the overall severity.&#xD;
&#xD;
          -  Subjects must be in good health and free from any clinically significant disease that&#xD;
             might interfere with the study evaluations.&#xD;
&#xD;
          -  Subject must be able to understand the requirements of the study and willing to comply&#xD;
             with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable&#xD;
             angina, or myocardial infarction) within the last 6 months.&#xD;
&#xD;
          -  Subjects with abnormal findings - physical or laboratory - that are considered by the&#xD;
             investigator to be clinically important and indicative of conditions that might&#xD;
             complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous&#xD;
             candidiasis, or bacterial skin infection.&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to study medications or their components.&#xD;
&#xD;
          -  Subjects who have a recent history or who are currently known to abuse alcohol or&#xD;
             drugs.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Hemodialysis or chronic ambulatory peritoneal dialysis therapy.&#xD;
&#xD;
          -  Current diagnosis of immunocompromising conditions.&#xD;
&#xD;
          -  Atopic or contact dermatitis.&#xD;
&#xD;
          -  Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.&#xD;
&#xD;
          -  Female subject who is pregnant or lactating, who is not using or does not agree to use&#xD;
             an acceptable form of contraception during the study, or who intends to become&#xD;
             pregnant during the study (females who are surgically sterilized for at least 2 years&#xD;
             are not considered to be of childbearing potential).&#xD;
&#xD;
          -  Subjects using the following medications:&#xD;
&#xD;
               -  Topical anti-fungal therapy, powders or topical corticosteroids applied within 14&#xD;
                  days prior to randomization. Terbinafine, butenafine, and naftifine (topical)&#xD;
                  within 30 days prior to randomization.&#xD;
&#xD;
               -  Oral anti-fungal therapies within 3 months of randomization (8 months for oral&#xD;
                  terbinafine).&#xD;
&#xD;
               -  Systemic antibiotic or corticosteroid treatment within 30 days of randomization.&#xD;
&#xD;
               -  Any other significant treatments, except hormonal contraception and multivitamin,&#xD;
                  at the discretion of the investigator that would interfere with study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Plaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Investigational Site # 501001</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site # 501002</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 180002</name>
      <address>
        <city>San Cristobal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 180001</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site # 504001</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>Dominican Republic</country>
    <country>Honduras</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <disposition_first_submitted>March 26, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2015</disposition_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea cruris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

